A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)
Study sponsor: Immunic AG
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-01-12Actual
Enrollment · participants234Actual
Source updated2024-11-13Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.